SLC19A3

Across TCGA pan-cancer cohorts, SLC19A3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC19A3 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLC19A3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC19A3 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LIHC, READ, and STAD are the cancer types where SLC19A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
READ	OS	Median	III,IV	0.289	0.932	<.001	15	view →
STAD	DFS	Median	III,IV	1.000	0.337	.038	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	III,IV	0.228	0.677	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC19A3–LIHC (DFS)

Open the LIHC breakdown →